Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hormonal changes with cholesterol reduction: a double-blind pilot study.

T Ormiston1, O M Wolkowitz, V I Reus

  • 1Department of Internal Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA. thomas.ormiston@hhs.co.santa-clara.ca.us

Journal of Clinical Pharmacy and Therapeutics
|January 30, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whole-genome DNA methylation status associated with clinical PTSD measures of OIF/OEF veterans.

Translational psychiatry·2017
Same author

Depression, telomeres and mitochondrial DNA: between- and within-person associations from a 10-year longitudinal study.

Molecular psychiatry·2017
Same author

Alterations in leukocyte transcriptional control pathway activity associated with major depressive disorder and antidepressant treatment.

Translational psychiatry·2016
Same author

Peripheral telomere length and hippocampal volume in adolescents with major depressive disorder.

Translational psychiatry·2015
Same author

Telomere length and cortisol reactivity in children of depressed mothers.

Molecular psychiatry·2014
Same author

Major depressive disorder and accelerated cellular aging: results from a large psychiatric cohort study.

Molecular psychiatry·2013
Same journal

Impact of pharmacist-initiated educational interventions on improving medication reconciliation practice in geriatric inpatients during hospital admission in Vietnam.

Journal of clinical pharmacy and therapeutics·2022
Same journal

Evaluation of off-label anti-vascular endothelial growth factor and steroid implant medication uses in macular edema due to retinal vein occlusion in Turkey.

Journal of clinical pharmacy and therapeutics·2022
Same journal

A descriptive analysis of pharmacological management of aggression and/or agitation in patients with traumatic brain injury in a Southwest Virginia inpatient population.

Journal of clinical pharmacy and therapeutics·2022
Same journal

Effects of caregiver counselling on medication persistence and adherence in patients with dementia at a pharmacist-managed clinic: A pilot study.

Journal of clinical pharmacy and therapeutics·2022
Same journal

The 50% and 95% effective doses of remimazolam tosilate with adjuvant sufentanil for sedation in patients with liver cirrhosis undergoing oesophagogastric varices screening endoscopy.

Journal of clinical pharmacy and therapeutics·2022
Same journal

Tumour necrosis factor inhibitor combined with intravenous immunoglobulin and heparin for treatment of recurrent spontaneous abortion: A two-centre, retrospective, cohort study.

Journal of clinical pharmacy and therapeutics·2022
See all related articles

Cholesterol-lowering drug treatment may alter hormone levels. This study found significant increases in dopamine and homovanillic acid (HVA) alongside decreased cholesterol in subjects.

Area of Science:

  • Endocrinology
  • Neurochemistry
  • Pharmacology

Background:

  • Lowering high serum cholesterol may be linked to non-cardiac mortality, possibly via behavioral changes.
  • Such mortality endpoints are considered rare.

Purpose of the Study:

  • To investigate if hormonal changes occur with pharmacologically induced decreases in serum cholesterol.
  • To explore potential neurochemical alterations associated with cholesterol reduction.

Main Methods:

  • Measurements of cholesterol, dopamine, homovanillic acid (HVA), serotonin, 5-HIAA, testosterone, cortisol, and pregnenolone.
  • Data collected at baseline and after 4 weeks of cholesterol-lowering treatment.

Main Results:

  • Significant decline in serum cholesterol levels observed within 4 weeks.

Related Experiment Videos

  • Concomitant significant increase in dopamine and homovanillic acid (HVA) levels noted.

    • Conclusions:

    • Cholesterol-lowering drug treatment may be associated with hormonal perturbations.
    • This preliminary study suggests a link between cholesterol reduction and changes in neurotransmitter metabolites.